Protalix BioTherapeutics
PLX
PLX
63 hedge funds and large institutions have $21M invested in Protalix BioTherapeutics in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
40% more funds holding
Funds holding: 45 → 63 (+18)
4.52% more ownership
Funds ownership: 5.97% → 10.49% (+4.5%)
Holders
63
Holding in Top 10
–
Calls
$838K
Puts
$166K
Top Buyers
| 1 | +$2.2M | |
| 2 | +$1.47M | |
| 3 | +$1.31M | |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.24M |
| 5 |
Goldman Sachs
New York
|
+$614K |
Top Sellers
| 1 | -$366K | |
| 2 | -$247K | |
| 3 | -$222K | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$120K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$89.9K |
